BMRN · Insider Trading
BioMarin Pharmaceuticals Inc
Every open-market purchase and sale reported by BMRN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-01 | Gregory R Friberg | EVP, Chief R&D Officer | F | −4,086 | −$245.16K |
| 2026-09-14 | Robert M Plenge | Director | A | +6,140 | — |
| 2026-09-03 | George Eric Davis | EVP, Chief Legal Officer | Sell | −17,557 | −$1.16M |
| 2026-06-04 | Elizabeth M Anderson | Director | A | +7,490 | — |
| 2026-06-04 | Barbara W. Bodem | Director | A | +7,490 | — |
| 2026-06-04 | Ian T Clark | Director | A | +7,490 | — |
| 2026-06-04 | Willard H Dere | Director | A | +7,490 | — |
| 2026-06-04 | Mark J Enyedy | Director | A | +7,490 | — |
| 2026-06-04 | Robert J. Hombach | Director | A | +7,490 | — |
| 2026-06-04 | Maykin Ho | Director | A | +7,490 | — |
| 2026-06-04 | Timothy P Walbert | Director | A | +7,490 | — |
| 2026-06-04 | Athena Countouriotis | Director | A | +7,490 | — |
| 2026-05-21 | Cristin Hubbard | EVP, Chief Commercial Officer | F | −2,318 | −$116.36K |
| 2026-05-11 | Gregory R Friberg | EVP, Chief R&D Officer | Sell | −3,281 | −$176.68K |
| 2026-03-19 | Alexander Hardy | Chief Executive Officer | F | −4,252 | −$238.32K |
| 2026-03-19 | Brian Mueller | EVP, Chief Financial Officer | F | −2,117 | −$118.66K |
| 2026-03-19 | Charles Greg Guyer | EVP, Chief Technical Officer | F | −1,693 | −$94.89K |
| 2026-03-19 | George Eric Davis | EVP, Chief Legal Officer | F | −1,273 | −$71.35K |
| 2026-03-18 | Gregory R Friberg | EVP, Chief R&D Officer | MIXED | +17,521 | −$91.31K |
| 2026-03-18 | Cristin Hubbard | EVP, Chief Commercial Officer | MIXED | +14,165 | −$69.78K |
| 2026-03-17 | Alexander Hardy | Chief Executive Officer | MIXED | +59,499 | −$172.08K |
| 2026-03-17 | Brian Mueller | EVP, Chief Financial Officer | MIXED | +8,795 | −$581.88K |
| 2026-03-17 | George Eric Davis | EVP, Chief Legal Officer | MIXED | +7,393 | −$419.93K |
| 2026-03-17 | Charles Greg Guyer | EVP, Chief Technical Officer | MIXED | +5,881 | −$532.97K |
| 2026-03-12 | Charles Greg Guyer | EVP, Chief Technical Officer | Sell | −16,486 | −$996.74K |
| 2026-02-26 | Brian Mueller | EVP, Chief Financial Officer | A | +16,482 | — |
| 2026-02-26 | George Eric Davis | EVP, Chief Legal Officer | MIXED | −10,837 | −$1.60M |
| 2026-02-26 | Gregory R Friberg | EVP, Chief R&D Officer | Sell | −6,326 | −$381.94K |
| 2026-02-26 | Charles Greg Guyer | EVP, Chief Technical Officer | A | +15,222 | — |
| 2026-01-22 | Rashmi Virendra Ramchandani | VP, Chief Accounting Officer | A | +25,610 | — |
| 2025-12-02 | Alexander Hardy | Chief Executive Officer | MIXED | −16,195 | −$891.55K |
| 2025-10-02 | Gregory R Friberg | EVP, Chief R&D Officer | F | −3,304 | −$178.94K |
| 2025-08-05 | Ian T Clark | Director | A | +7,000 | — |
| 2025-05-22 | Elizabeth M Anderson | Director | A | +6,650 | — |
| 2025-05-22 | Barbara W. Bodem | Director | A | +6,650 | — |
| 2025-05-22 | Athena Countouriotis | Director | A | +6,650 | — |
| 2025-05-22 | Willard H Dere | Director | A | +6,650 | — |
| 2025-05-22 | Mark J Enyedy | Director | A | +6,650 | — |
| 2025-05-22 | Maykin Ho | Director | A | +6,650 | — |
| 2025-05-22 | Robert J. Hombach | Director | A | +6,650 | — |
| 2025-05-22 | Richard A Meier | Director | A | +6,650 | — |
| 2025-05-22 | Timothy P Walbert | Director | A | +6,650 | — |
| 2025-05-22 | Cristin Hubbard | EVP, Chief Commercial Officer | F | −2,155 | −$129.15K |
| 2025-05-20 | Erin Burkhart | GVP, Chief Accounting Officer | MIXED | −2,782 | −$164.96K |
| 2025-05-06 | Cristin Hubbard | EVP, Chief Commercial Officer | MIXED | — | −$2.94K |
| 2025-03-20 | Erin Burkhart | GVP, Chief Accounting Officer | Sell | −1,295 | −$92.62K |
| 2025-03-18 | Alexander Hardy | Chief Executive Officer | MIXED | +41,427 | −$203.67K |
| 2025-03-18 | Brian Mueller | EVP, Chief Financial Officer | MIXED | −1,857 | −$1.28M |
| 2025-03-18 | Charles Greg Guyer | EVP, Chief Technical Officer | MIXED | −6,817 | −$1.40M |
| 2025-03-18 | Gregory R Friberg | EVP, Chief R&D Officer | A | +17,750 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Alexander Hardy | Chief Executive Officer | 214,635 | $12.28M |
| Richard A Meier | Director | 127,426 | $7.29M |
| Brian Mueller | EVP, Chief Financial Officer | 123,314 | $7.05M |
| Charles Greg Guyer | EVP, Chief Technical Officer | 84,140 | $4.81M |
| George Eric Davis | EVP, Chief Legal Officer | 61,003 | $3.49M |
| Robert J. Hombach | Director | 49,360 | $2.82M |
| Gregory R Friberg | EVP, Chief R&D Officer | 47,732 | $2.73M |
| Willard H Dere | Director | 46,440 | $2.66M |
| Cristin Hubbard | EVP, Chief Commercial Officer | 42,472 | $2.43M |
| Elizabeth M Anderson | Director | 41,940 | $2.40M |
| Maykin Ho | Director | 35,500 | $2.03M |
| Rashmi Virendra Ramchandani | VP, Chief Accounting Officer | 25,610 | $1.46M |
| Barbara W. Bodem | Director | 21,045 | $1.20M |
| Mark J Enyedy | Director | 21,040 | $1.20M |
| Athena Countouriotis | Director | 21,040 | $1.20M |
| Timothy P Walbert | Director | 17,686 | $1.01M |
| Ian T Clark | Director | 14,490 | $828.83K |
| Erin Burkhart | GVP, Chief Accounting Officer | 14,173 | $810.70K |
| Robert M Plenge | Director | 6,140 | $351.21K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BMRN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.